Check-In & Morning Coffee
8.00
Workshop A
9.00
Leveraging Artificial Intelligence to Delineate RNA Functionality & Inform Design Strategies for Therapeutic Applications
Yaoqi Zhou, Professor, Shenzen Bay Laboratory
Wonil Kim, Chief Scientific Officer, Aston Sci
Being able to design and develop an RNA therapeutic or vaccine platforms from concept into an effective drug product can be a challenge especially with new and emerging technologies that require thorough analysis and regulatory validation. However, without this, there would be limited progress to expand the potential of RNA. This workshop will help give you the foundation to using artificial intelligence and machine learning methodologies to understand RNA structure function relationships and navigate challenges with target identification and sequence design to boost your therapeutic, vaccine, gene editing or cell therapy pipelines.
Spotlight Case Study
Decoding RNA: From Sequence to Structure for Functional Insight & Therapeutic Innovation
- Deciphering RNA structure is paramount for understanding its biological function and unlocking therapeutic potential
- Showcasing the latest advancement in RNA sequence analysis, RNA language models, secondary structure base pair prediction, and 3D structure prediction
- Demonstrating that integrating covariance analysis with mobility based selections enabled unprecedented accuracy in 2D and 3D structure prediction
- Improving sequence based prediction and structural elucidation will be useful for developing RNA-based therapeutics, such as optimizing mRNA stability
and translation, designing antisense oligonucleotides (ASOs), and discovering targetable RNA structures
Networking Lunch Break
12.00
Workshop B
1.00
Crafting the Perfect Process Development & CMC Strategy to Improve RNA Product Quality & Commercial Manufacturability
Xueliang Yu, Vice President, Starna Therapeutics
Yasumasa Ota, mRNA technology Leader. Meiji Seika Pharma
Xian Zeng, Chief Executive Officer & Co-Founder, Byterna Therapeutics
With circular RNA technology paving the way forward into clinical trials and in vivo
cell engineering becoming a promising new tool for cell therapy, the challenge now
focuses on developing a scalable manufacturing system and CMC strategy to support efficiency scale up from early R&D stages. This workshop will provide you with key insights into CMC strategies to go from raw material to product with streamlined processes, key considerations at each phase of development to scaling for clinical and commercial capacity.
Spotlight Case Study 1
Unique Challenges in RNA-LNP for In Vivo CAR-T
- Delivery Efficiency: Ensuring targeted delivery and transfection of CAR-encoding RNA to T cells in vivo
- Stability and Scalability: Overcoming instability of RNA-LNP formulations during manufacturing
- Immunogenicity and Safety: Minimizing unintended immune activation while maintaining therapeutic efficacy
Spotlight Case Study 2
Development & CMC Perspectives on the Next-Generation sa-mRNA Vaccine, KOSTAIVE